康寧傑瑞(09966.HK)KN046聯合治療臨床研究完成首例患者給藥
康寧傑瑞(09966.HK)公佈,旗下核心產品PD-L1/CTLA-4雙特異性抗體(KN046),聯合澤璟制藥甲苯磺酸多納非尼片治療晚期肝細胞癌第一及第二期臨床研究已完成首例患者給藥。
該臨床研究採用多中心、開放、劑量遞增和劑量擴展的設計,基於兩藥在抗腫瘤方面的協同作用機制,旨在評估KN046聯合多納非尼在晚期肝細胞癌患者中的安全性、耐受性和有效性,試驗計劃在全國範圍內約6家研究中心開展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.